Spherix Global Insights
‘Don’t shy away’ from JAKs in IBD: Monitor patient outcomes, understand potential risks
Despite an existing class-wide black box warning, 45% of health care providers felt cardiovascular concerns related to Janus kinase inhibitors “were irrelevant” to patients with inflammatory bowel disease, according to survey results.
Study reveals ‘multifaceted consequences’ of cisplatin shortage
Findings presented at ASCO Quality Care Symposium provided new insights into the effects last year’s cisplatin shortage had on patients with head and neck cancer.
‘On the cusp of a new era’: Promising drugs may tackle unmet needs in giant cell arteritis
Nearly all rheumatologists who responded to a recent survey reported patients with giant cell arteritis are in dire need of new treatments, according to a market analysis from Spherix Global Insights.
IL-17 inhibitors may break TNFi ‘glass ceiling’ in psoriatic arthritis prescribing
Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis from Spherix Global Insights.
Neurologists mired in ‘wait and see’ approach to Leqembi prescription, administration
The FDA’s approval of Leqembi in July 2023 triggered a wave of discussion in the medical community on how to prescribe and properly administer the amyloid-targeting antibody to treat those diagnosed with Alzheimer’s disease.
Experts weigh current, future options for AMD management
The past 2 years have brought a decisive leap forward in the management of age-related macular degeneration.
‘Exciting time’: Biologic use in moderate to severe lupus rose 45% since 2021
Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights.
‘Efficacy will lead’ as first-line JAK inhibitor use picks up in moderate to severe UC
Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors as first-line treatment among patients with severe ulcerative colitis, according to survey results.
Amjevita leads Humira biosimilars in clinician comfort as rheumatologists remain wary
Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights.
Chart review shows nephrologists prescribing more SGLT2 inhibitors
A chart review completed by Spherix Global Insights shows that more nephrologists are using SGLT2 inhibitors to treat patients with chronic kidney disease, according to a press release.